Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Lymphoma

  Free Subscription


4 Br J Haematol
4 J Clin Oncol
1 Mod Pathol

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Br J Haematol

  1. WITTE H, Biersack H, Kopelke S, Rades D, et al
    The Glasgow prognostic score at diagnosis is an independent predictor of survival in advanced stage classical Hodgkin lymphoma.
    Br J Haematol. 2018 May 22. doi: 10.1111/bjh.15198.
    PubMed     Text format    

  2. SHI J, Bodo J, Zhao X, Durkin L, et al
    SLAMF7 (CD319/CS1) is expressed in plasmablastic lymphoma and is a potential diagnostic marker and therapeutic target.
    Br J Haematol. 2018 May 22. doi: 10.1111/bjh.15393.
    PubMed     Text format    

  3. MARALDO MV, Illidge TM
    How do we move towards a personalised approach in the treatment of Early Hodgkin lymphoma?
    Br J Haematol. 2018 May 22. doi: 10.1111/bjh.15256.
    PubMed     Text format    

  4. JAIN P, Romaguera J, Srour SA, Lee HJ, et al
    Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL).
    Br J Haematol. 2018 May 22. doi: 10.1111/bjh.15411.
    PubMed     Text format     Abstract available

    J Clin Oncol

  5. MESGUICH C, Bouabdallah K, Milpied N, Hindie E, et al
    Additional Evidence That End-of-Treatment Fluorodeoxyglucose-Positron Emission Tomography Evaluation Is Necessary in Advanced Hodgkin Lymphoma.
    J Clin Oncol. 2018 May 23:JCO2018786780. doi: 10.1200/JCO.2018.78.6780.
    PubMed     Text format    

  6. ADAMS HJA, Kwee TC
    Strikingly Heterogeneous Results Among Studies on Interim Fluorodeoxyglucose-Positron Emission Tomography-Adapted Treatment in Advanced-Stage Hodgkin Lymphoma.
    J Clin Oncol. 2018 May 23:JCO2018782524. doi: 10.1200/JCO.2018.78.2524.
    PubMed     Text format    

  7. MERRYMAN RW, LaCasce AS
    Response-Adapted Therapy in Aggressive Lymphoma: Not Yet Ready for Clinical Care.
    J Clin Oncol. 2018 May 22:JCO2018789362. doi: 10.1200/JCO.2018.78.9362.
    PubMed     Text format    

  8. LETAI A
    Targeting B-Cell Lymphoma 2: A Lethal Shortcut in Del(17p) Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2018 May 22:JCO2018782763. doi: 10.1200/JCO.2018.78.2763.
    PubMed     Text format    

    Mod Pathol

  9. HUANG W, Medeiros LJ, Lin P, Wang W, et al
    MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas.
    Mod Pathol. 2018 May 21. pii: 10.1038/s41379-018-0067.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.